Professional Documents
Culture Documents
PDF Personalized Nutrition As Medical Therapy For High Risk Diseases 1St Edition Nilanjana Maulik Editor Ebook Full Chapter
PDF Personalized Nutrition As Medical Therapy For High Risk Diseases 1St Edition Nilanjana Maulik Editor Ebook Full Chapter
PDF Personalized Nutrition As Medical Therapy For High Risk Diseases 1St Edition Nilanjana Maulik Editor Ebook Full Chapter
https://textbookfull.com/product/yoga-therapy-a-personalized-
approach-for-your-active-lifestyle-1st-edition-kristen-butera/
https://textbookfull.com/product/working-with-high-risk-
adolescents-an-individualized-family-therapy-approach-1st-
edition-matthew-d-selekman/
https://textbookfull.com/product/personalized-computational-
hemodynamics-models-methods-and-applications-for-vascular-
surgery-and-antitumor-therapy-1st-edition-yuri-vassilevski/
https://textbookfull.com/product/williams-basic-nutrition-diet-
therapy-15th-edition-staci-nix-mcintosh/
Nutrition and Lifestyle in Neurological Autoimmune
Diseases: Multiple Sclerosis 1st Edition Ronald Ross
Watson
https://textbookfull.com/product/nutrition-and-lifestyle-in-
neurological-autoimmune-diseases-multiple-sclerosis-1st-edition-
ronald-ross-watson/
https://textbookfull.com/product/healthful-eating-as-lifestyle-
heal-integrative-prevention-for-non-communicable-diseases-1st-
edition-shirin-anil/
https://textbookfull.com/product/anesthesia-in-high-risk-
patients-1st-edition-jean-luc-fellahi/
https://textbookfull.com/product/high-risk-pollutants-in-
wastewater-1st-edition-hongqiang-ren-editor/
https://textbookfull.com/product/bioactive-food-as-dietary-
interventions-for-arthritis-and-related-inflammatory-diseases-
preedy/
Personalized Nutrition as
Medical Therapy for
High-Risk Diseases
Personalized Nutrition as
Medical Therapy for
High-Risk Diseases
Edited by
Nilanjana Maulik
First edition published 2020
by CRC Press
6000 Broken Sound Parkway NW, Suite 300,
Boca Raton, FL 33487-2742
Reasonable efforts have been made to publish reliable data and information, but the author and publisher can-
not assume responsibility for the validity of all materials or the consequences of their use. The authors and
publishers have attempted to trace the copyright holders of all material reproduced in this publication and
apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright
material has not been acknowledged please write and let us know so we may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmit-
ted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented,
including photocopying, microflming, and recording, or in any information storage or retrieval system, with-
out written permission from the publishers.
For permission to photocopy or use material electronically from this work, access www.copyright.com or
contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400.
For works that are not available on CCC please contact mpkbookspermissions@tandf.co.uk
Trademark notice: Product or corporate names may be trademarks or registered trademarks, and are used only
for identifcation and explanation without intent to infringe.
Chapter 1 Introduction...........................................................................................1
Dilip Ghosh
vii
viii Contents
ix
x Preface
xi
Editor
Nilanjana Maulik is a well-established and highly reputed cardiovascular scientist.
She is an expert in the feld of vascularization and cardiac regeneration and develops
therapeutic strategies for ischemic heart disease. Her laboratory has identifed impor-
tant pro-angiogenic molecules that play an important role in therapeutic angiogenesis
using various preclinical models and disease conditions. Her research has advanced
knowledge in the areas of angiogenesis and revascularization of the ischemic myo-
cardium. Dr Maulik received her PhD in Biochemistry from Calcutta University,
India. After completion of her PhD, Dr Maulik joined the Department of Surgery at
University of Connecticut Health as a research fellow. She has continued her service
there as a faculty member, and was promoted to tenured professor. Dr Maulik also
serves as a faculty member in the Cell Biology graduate program at the University
of Connecticut Health. She has been heavily involved in NIH-funded research all
her career. She also serves as an expert (cardiovascular) in the NIH study sections
regularly; she frequently gives invited lectures at national and international scien-
tifc conferences. She has trained more than 150 scientists/fellows/residents, most
of whom are actively engaged in professional careers all over the world. Dr Maulik
is a member of several prestigious societies including the Federation of American
Societies for Experimental Biology (FASEB), the American Heart Association
(AHA), the International Society of Heart Research (ISHR), the American College
of Nutrition (ACN) and the International College of Angiology (ICA). Presently,
she is on the editorial boards of several major cardiovascular journals and served
as Editor-in-Chief of the prestigious journal Molecular Biology Reports (Springer
Press). She is a Fellow of the International Academy of Cardiovascular Sciences
(IACS, Canada), ACN and AHA. She has published more than 210 original peer-
reviewed articles and almost 36 book chapters. She has also edited four books on
epigenetics, nutrition and cardiovascular diseases for CRC/Springer Press. Lastly,
Dr Maulik has organized several international conferences, symposia and delivered
more than 125 lectures all around the world.
xiii
Contributors
Diego Accorsi Dilip Ghosh
School of Medicine Nutriconnect
University of Connecticut Western Sydney University,
Farmington, Connecticut Australia
xv
xvi Contributors
CONTENTS
1.1 Introduction ...................................................................................................... 1
1.2 What Does Personalization Mean?................................................................... 2
1.3 Where to Go from Here? ..................................................................................2
1.4 Medicalization of Food..................................................................................... 2
1.5 The Genome-Based Health Concept ................................................................ 3
1.6 Way Forward.....................................................................................................3
References..................................................................................................................4
1.1 INTRODUCTION
Today’s nutritional and dietary supplement market is considerably different than it
was 10–15 years ago. Consumer demands for healthy foods have been changing
considerably every year, particularly in the last decade. More and more, consum-
ers believe that foods with specifc functionality contribute directly to their health.
Foods today are not only considered as a vehicle to satisfy hunger and to provide
necessary nutrients but also to prevent nutrition-related diseases and improve physi-
cal and mental well-being. In this scenario, functional food and active ingredients
play an outstanding role. From an economic perspective, this increasing demand on
such foods/nutrition can be justifed by the increasing cost of healthcare, the steady
increase in life expectancy, including infants, and the aspiration and desire of older
people for improved quality of their later years (Roberfroid 2000).
In the 21st century humankind is facing a global pandemic of diet-related chronic
disease and preventable disorders that include cardiovascular disease, obesity and dia-
betes, cancers, osteoporosis and myriad infammatory disorders. These are the leading
cause of the global healthcare burden. Virtually most of these disorders are diet-related
and, not surprisingly, are not responding well to pharmaceutical intervention. The
heavily burdened and eroding healthcare system is in need of an etiology-based model
that addresses the underlying molecular basis of a patient/consumer’s dysfunction and
develops therapeutic and preventive strategies that will include the biochemical-molec-
ular individuality of each person. A genetic predisposition model of health and disease
is emerging from the Human Genome Project that opens up etiology-based care and
will be almost equivalent to the current evidence-based pharmaceutical framework.
The current medical model of genetic determinism is now being challenged by
the emerging concept of genetic susceptibility which enables one to change one’s
health trajectory through the judicious use of diet and lifestyle. In this scenario, inno-
vative, evidence-based food/nutritional and dietary supplements have a signifcant
role in changing our destiny.
1
2 Personalized Nutrition as Medical Therapy for High-Risk Diseases
is aspirin (acetylsalicylic acid), originally derived from the bark of the white willow tree.
Other examples include the immunosuppressive cyclosporines, the anthracycline antibi-
otics and the HMG-CoA reductase inhibitors, commonly known as statins. Traditionally,
pharmaceuticals have been used to cure diseases or to alleviate the symptoms of disease.
Nutrition, on the other hand, is primarily aimed at preventing diseases by providing the
body with the optimal balance of macro- and micronutrients needed for good health.
Due to the emerging knowledge of disease, medicines are now increasingly being
used to lower risk factors, and thereby to prevent chronic diseases. Prime examples
are blood pressure-lowering and blood lipid-lowering agents which reduce the risk of
cardiovascular disease. The appearance of functional foods and dietary supplements
on the market has further blurred the distinction between pharma and nutrition.
However, it is important to distinguish the target and effective outcome of pharma
and nutra intervention.
nutritionists. Recent studies published in last few years not only underline the thera-
peutic potential of lifestyle interventions but are also generating valuable insights in
the complex and dynamic transition from health to disease continuum.
This book discusses the recent developments in the pharmaceutical-nutrition
interface and relevant mechanisms, including receptors and other targets. A few
clinical practice-based examples are cited in this book.
Several dedicated chapters deal with nutraceutical intervention to manage or treat
physiological conditions and diseases such as cardiovascular disease, hypertension,
Crohn’s disease, chronic kidney disease, hypercholesteremia, maternal and offspring
metabolic disorders and psychological disorders. Two more interesting areas covered
in this book are the role of caloric restriction in obesity and diabetic heart disease
and the effect of high carbohydrate diet-induced metabolic syndrome in the over-
weight body.
It is evident that pharmaceutical industry will beneft from nutritional genomics
knowledge and a physiological approach that puts health above diseases and medical
conditions (Ghosh, Skinner et al. 2007). This will help us to get a better understand-
ing about the transition between health, homeostatic resilience and chronic disease,
to develop better and more tailored treatment options. The personalized nutrition
market is in many ways an unknown space for the ‘Big Pharma’ players. To over-
come this weakness, they are taking on strategic partnerships, collaborations and
acquisitions. As a result, we should expect further partnerships between big pharma
companies and tech start-ups enabling them to be in this growing trend for personal-
ized products.
Experience shows that commercial providers are keen to proceed to the market
with products before the scientifc evidence is established. This can only be checked
if there are national and international agreed guidelines for using genotype-based
advice in personalized nutrition. The Food4Me consortium (Grimaldi, van Ommen
et al. 2017) has proposed such guidelines recently, but the research and regulatory
communities have to evaluate and agree on the proposed guidelines.
REFERENCES
Brown, L. and F. van der Ouderaa (2007). “Nutritional genomics: food industry applications
from farm to fork.” Br J Nutr 97(6): 1027–1035.
de Roos, B. (2013). “Personalised nutrition: ready for practice?” Proc Nutr Soc 72(1): 48–52.
Ghosh, D., M. A. Skinner, et al. (2007). “Pharmacogenomics and nutrigenomics: synergies
and differences.” Eur J Clin Nutr 61(5): 567–574.
Grimaldi, K. A., B. van Ommen, et al. (2017). “Proposed guidelines to evaluate scientifc
validity and evidence for genotype-based dietary advice.” Genes Nutr 12: 35.
Roberfroid, M. B. (2000). “Concepts and strategy of functional food science: the European
perspective.” Am J Clin Nutr 71(6 Suppl): 1660S–1664S; discussion 1674S–1665S.
Ruemmele, F. M. and H. Garnier-Lengline (2012). “Why are genetics important for nutrition?
Lessons from epigenetic research.” Ann Nutr Metab 60(3 Suppl): 38–43.
2 The New Era of Nutrition
Personalized Nutrition
CONTENTS
2.1 Introduction ......................................................................................................5
2.1.1 Defning Personalized Nutrition........................................................... 6
2.1.2 Origins of Personalized Nutrition as a Formal Scientifc Ideology......6
2.2 Theoretical Basis for Personalized Nutrition ................................................... 8
2.3 Current Perspectives on Personalized Nutrition...............................................8
2.3.1 Nutrient-Gene Interactions ...................................................................9
2.3.1.1 Biomarkers.............................................................................9
2.3.2 Altering Human Behavior .................................................................. 13
2.3.3 Age and Stages of Life........................................................................ 16
2.3.4 Gender................................................................................................. 16
2.3.5 Environment: The Exposome ............................................................. 19
2.3.5.1 The Microbiome................................................................... 19
2.3.6 Personalized Nutritional Strategies for Athletic Performance ...........20
2.4 Closing Remarks.............................................................................................20
Abbreviations ...........................................................................................................20
References................................................................................................................ 21
2.1 INTRODUCTION
Diet and nutrition have historically been regarded as important factors in the promo-
tion and maintenance of health throughout the entire life span and had until very
recently played a leading role in the management of disease, according to epide-
miological studies (Kussmann and Fay 2008). For example, Hippocrates, heralded
as the father of modern medicine, once said: ‘Let the food be thy medicine and the
medicine be thy food.’ Since then our understanding of the specifc microbiological
mechanisms through which nutrition contributes to overall health and disease con-
tinues to grow but, with the advent of pharmacotherapy, nutrition has taken a back-
seat as a tool to improve health in modern medicine. Nutritional recommendations
for the otherwise healthy often follow a generalized, ‘one-size-fts-all’ approach
aimed primarily at weight loss, while formal nutritional guidelines as prescribed
by clinicians apply only to subpopulations at risk, such as diabetics, while failing to
5
6 Personalized Nutrition as Medical Therapy for High-Risk Diseases
TABLE 2.1
Descriptors and Defnitions
In common with other scientifc felds in their early development, multiple concepts and descriptors are
used in personalized nutrition, sometimes without rigorous defnition. In addition to the term personalized
nutrition, many other terms are used—for example, precision nutrition, stratifed nutrition, tailored
nutrition and individually tailored nutrition. We have attempted to group the descriptors as follows:
• Stratifed and tailored nutrition are similar (if not synonymous). These approaches attempt to group
individuals with shared characteristics and to deliver nutritional intervention/advice that is suited to
each group.
• Personalized nutrition and individually tailored nutrition mean similar things and go a step further by
attempting to deliver nutritional intervention/advice suited to each individual.
• Precision nutrition is the most ambitious of the descriptors. It suggests that it is possible to have
suffcient quantitative understanding about the complex relationships between an individual, his/her
food consumption and his/her phenotype (including health) to offer nutritional intervention/advice,
which is known to be individually benefcial. The degree of scientifc certainty required for precision
nutrition is much greater than that required for the other approaches.
• Nutrigenetics is an aspect of personalized nutrition that studies the different phenotypic responses (i.e.
weight, blood pressure, plasma cholesterol or glucose levels) to a specifc diet (i.e. low fat or
Mediterranean diets), depending on the genotype of the individual.
• Nutrigenomics involves the characterization of all gene products affected by nutrients and their
metabolic consequences.
• Exposome is the collection of environmental factors, such as stress, physical activity and diet, to
which an individual is exposed and which may affect health. As one moves from stratifed to
personalized to precision nutrition, it becomes necessary to apply more and more dimensions or
characteristics to achieve the desired goal. For example, stratifcation could be undertaken using one,
or a few, dimensions such as age, gender or health status. In contrast, given the complexity of
relationships between individual diet and phenotype, deployment of a wide range of dimensions/
characteristics, perhaps including ‘big data’ approaches, would be necessary to achieve the goal of
precision nutrition. An exception to this broad generalization is the management of inborn errors of
metabolism such as phenylketonuria, where ‘precision nutrition’ can be achieved using information on
a single characteristic—that is, genotype.
• Epigenomics is a branch of genomics concerned with the epigenetic changes (methylation, histone
modifcation, microRNAs) that modify the expression and function of the genetic material of an
organism.
• Metabolomics is the scientifc study and analysis of the metabolites (usually restricted to small
molecules, i.e. <900 daltons) produced by a cell, tissue or organism.
• Microbiomics is the study of the microbiome, the totality of microbes in specifc environments (i.e.
the human gut).
of nutritional management. In a report by the Institute for the Future in Palo Alto,
2003, a suggestion was made that within a decade most adults would make at least
part of their nutritional choices based on knowledge of their genetic makeup and
inherent susceptibilities to different foods. While this prediction did not come to
fruition in its entirety by the proposed deadline, that decade did see the beginnings
of formalized, funded personalized nutritional research, including the Food4Me
8 Personalized Nutrition as Medical Therapy for High-Risk Diseases
consortium, which eventually led a fve-year project, the largest to date, exploring
various elements involved in personalized nutrition using complex multidisciplinary
approaches (Kraemer, Cordaro et al. 2016).
that in recent years much attention has been paid to deciphering the human genome
and its infuence on disease risk, genes are only a small part of a very broad picture.
There are many other factors, both intrinsic and extrinsic, such as age, stage of life
(pregnant, lactating, etc.), sex, race, ethnicity and cultural or religious backgrounds,
which can infuence the effect of diet on the body (Ordovas, Ferguson et al. 2018).
Due to the inherent complexity of analyzing all the factors that make an individual
unique, the biggest challenge of personalized nutrition is its study and execution in
real-life situations. Therefore, the process will not only require an understanding of
an individual’s genetic makeup and susceptibility, but also biological substantiation
of an individual’s responses to food/nutrient consumption manifested as changes in
specifc measurable parameters (biomarkers, microbiota), analysis of sociobehav-
ioral patterns, food choice and availability, troubleshooting obstacles at all points
in the pipeline, and clear demarcation of objectives to inspire and facilitate eating
pattern modifcation (Ordovas, Ferguson et al. 2018).
2.3.1.1 Biomarkers
In order to monitor changes to an individual’s physiology and gene expression, it
becomes necessary to use biomarkers; these can represent certain physiologic
parameters such as blood pressure, components of the metabolome, or may also
be one of many molecules involved in the complex cascades responsible for gene
expression. The most valuable biomarkers are those that are easy/cheap to obtain and
measure. It is also necessary to defne a normal range that equates to the “healthy
10 Personalized Nutrition as Medical Therapy for High-Risk Diseases
TABLE 2.2
Summary of Genetic Variants That Modify the Association between Various
Dietary Factors and Performance-Related Outcomes
Gene (RS Function Dietary Dietary Performance-Related
Number) Factor Sources Outcome
CYP1A2 Encodes CYP1A2 Caffeine Coffee, tea, Cardiovascular health,
(rs762551) liver enzyme: soda, energy endurance (Clenin et
metabolizes drinks, al., 2015; Haas &
caffeine; identifes caffeine Brownlie, 2001;
individuals as fast supplements Palatini et al., 2009;
or slow metaboliz- Soares, Schneider,
ers Valle, & Schenkel,
2018)
ADORA2A Regulates myocardial Caffeine Coffee, tea, Vigilance when fatigued,
(rs5751876 oxygen demand; soda, energy sleep quality (Begas,
increases coronary drinks, Kouvaras, Tsakalof,
circulation via caffeine Papakosta, &
vasodilation supplements Asprodini, 2007;
Ghotbi et al., 2007;
Hunter, St Clair
Gibson, Collins,
Lambert, & Noakes,
2002; Yang, Palmer, &
de Wit, 2010)
BCMO1 Converts pro-vitamin Vitamin A Bluefn tuna, Visuo-motor skills and
(rs11645428) A carotenoids hard goat immunity (Czarnewski,
toVitamin A cheese, eggs, Das, Parigi, &
mackerel, Villablanca, 2017;
carrots, Ferrucci et al., 2009;
sweet potato Garvican et al., 2014;
Lietz, Lange, &
Rimbach, 2010; Lietz,
Oxley, Leung, &
Hesketh, 2012; Palidis,
Wyder-Hodge, Fooken,
& Spering, 2017)
MTHFR Produces the Folate Edamame, Megaloblastic anemia
(rs1801133) enzyme methylene- chicken liver, and hyperhomocystein-
tetrahydrofolate lentils, emia risk (Curro et al.,
reductase, which is asparagus, 2016; Dinc, Yucel,
involved in the black beans, Taneli, & Sayin, 2016;
conversion of folic kale, Goyette et al., 1994;
acid and folate into avocado Guinotte et al., 2003)
their biologically
active form,
L-methylfolate
(Continued )
Defning Personalized Nutrition 11